Feature | September 26, 2014

Laser Atherectomy With Balloon Angioplasty More Effective Than PTA Alone

Results of EXCITE ISR Trial Reported at TCT 2014

September 26, 2014 — The first large prospective study to examine the effectiveness of laser atherectomy in the treatment of femoropopliteal in-stent restenosis (ISR) found that the procedure combined with percutaneous transluminal angioplasty (PTA) was more effective than PTA alone. Findings of the EXCITE ISR trial were reported at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Femoropopliteal stenting is an effective treatment for peripheral arterial disease. However, restenosis (re-narrowing or re-occlusion within the stented segment) is very common, with more than 115,000 ISR procedures performed each year in the United States. Once ISR develops, there is a 65 percent chance of recurrence after re-treatment with PTA.

Laser atherectomy is a minimally invasive catheter-based procedure that vaporizes plaque and thrombus, restoring blood flow. The multi-center, prospective, randomized, controlled EXCITE ISR trial compared the safety and efficacy of laser atherectomy with adjunctive PTA to PTA alone in the treatment of patients with femoropopliteal ISR. The primary efficacy endpoint was freedom from clinically driven target lesion revascularization (TLR) through six months of follow up. The primary safety endpoint was major adverse events (MAEs) at 30 days, including all-cause mortality, major amputation in the target limb, or TLR. Major inclusion criteria included ISR target lesions larger than or equal to 40 millimeters, vessel diameter between 5-7 millimeters, and Rutherford class one to four. The trial enrolled 250 patients at 40 clinical sites, randomizing them in 2:1 fashion: a total of 169 subjects were enrolled in the treatment arm (laser atherectomy and PTA) and 81 patients enrolled in the control arm (PTA alone). Both groups were similar in baseline demographics and lesion characteristics.

Lesion length averaged 190 millimeters and more than 30 percent of patients presented with total occlusion. Compared to PTA alone, laser atherectomy with PTA demonstrated superior procedural success (93.5 percent vs. 82.7 percent, p= 0.02). Freedom from TLR at six months was 73.5 percent for the laser atherectomy with PTA group compared to 51.8 percent for the PTA group (p < 0.005). The 30-day MAE rates were 5.8 percent for the laser atherectomy with PTA group compared to 20.8 percent for the PTA group (p < 0.001).

“EXCITE ISR demonstrates that laser atherectomy devices used with PTA are superior to PTA alone in treating even the most complex lesions in patients with femoropopliteal peripheral artery disease,” said lead investigator Eric Dippel, M.D. from the Genesis Heart Institute in Davenport, Iowa. “The procedure leads to better outcomes than the current practice and significantly reduces adverse events when treating in-stent restenosis compared to PTA alone.”

The EXCITE ISR trial was funded by Spectranetics. Dippel reported consulting fees/honoraria from Abbott Vascular, Boston Scientific, Covidien, and Spectranetics. He also reports equity in Spectranetics.

For more information: www.crf.org, www.tctconference.com

Related Content

Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Overlay Init